GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tevogen Bio Holdings Inc (FRA:G28) » Definitions » Cyclically Adjusted PS Ratio

Tevogen Bio Holdings (FRA:G28) Cyclically Adjusted PS Ratio : (As of Jun. 01, 2025)


View and export this data going back to 2024. Start your Free Trial

What is Tevogen Bio Holdings Cyclically Adjusted PS Ratio?

Tevogen Bio Holdings does not have a history long enough to calculate Cyclically Adjusted Revenue per Share. Therefore GuruFocus does not calculate Cyclically Adjusted PS Ratio for this company.

Shiller PE for Stocks: The True Measure of Stock Valuation


Tevogen Bio Holdings Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Tevogen Bio Holdings's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tevogen Bio Holdings Cyclically Adjusted PS Ratio Chart

Tevogen Bio Holdings Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PS Ratio
- - - -

Tevogen Bio Holdings Quarterly Data
Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Tevogen Bio Holdings's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Tevogen Bio Holdings's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tevogen Bio Holdings's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tevogen Bio Holdings's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Tevogen Bio Holdings's Cyclically Adjusted PS Ratio falls into.


;
;

Tevogen Bio Holdings Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Tevogen Bio Holdings does not have a history long enough to calculate Cyclically Adjusted Revenue per Share. Therefore GuruFocus does not calculate Cyclically Adjusted PS Ratio for this company.


Tevogen Bio Holdings  (FRA:G28) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Tevogen Bio Holdings Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Tevogen Bio Holdings's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Tevogen Bio Holdings Business Description

Traded in Other Exchanges
Address
15 Independence Boulevard, Warren, NJ, USA, 07059
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.

Tevogen Bio Holdings Headlines

No Headlines